Adaptive Biotechnologies Corporation
ADPTHealthcare|Biotechnology|US
$27.98
+1.15 (+4.29%)
Tangible Book / Share
$0.40
Cash / Share
$1.86
Clinical Trials (14)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06828991 A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP | Diffuse Large B-Cell Lymphoma (DLBCL) | P2 | Recruiting | 40 | Open-label | Mosunetuzumab |
| NCT06252675 Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma | Mantle Cell Lymphoma | P2 | Recruiting | 30 | Open-label | Obinutuzumab, Glofitamab, Pirtobrutinib |
| NCT04419519 Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax | Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) | P2 | Active | 81 | Open-label | Venetoclax monotherapy, Venetoclax with anti CD20 monoclonal antibody |
| NCT05271630 Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant | Multiple Myeloma | Active | 69 | — | Immunomodulatory Agent, Proteasome Inhibitor | |
| NCT05255354 Optimizing ctDNA-based MRD Assessment in DLBCL, MCL, and FL Patients Undergoing CAR Therapy | Follicular Lymphoma, Diffuse Large B Cell Lymphoma | Recruiting | 300 | — | — | |
| NCT02553642 Relationship Between Tumor Mutation Burden and Predicted Neo-antigen Burden in Patients With Advanced Melanoma or Bladder Cancer Treated With Nivolumab or Nivolumab Plus Ipilimumab (CA209-260) | Bladder Cancer, Melanoma | P2 | Completed | 81 | Open-label | Nivolumab, Nivolumab plus Ipilimumab |
| NCT06557330 MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | Lymphoma, Indolent Non-hodgkin Lymphoma | P2 | Not Yet Recruiting | 24 | Open-label | Bendamustine, Rituximab |
| NCT05112874 ImmuneSense™ COVID-19 Cross-Reactivity Study | Coronavirus Disease, SARS-CoV-2 Infection | Withdrawn | — | — | — | |
| NCT05769829 ImmuneSense™ IBD Study | Inflammatory Bowel Diseases | Terminated | 484 | — | — | |
| NCT04583982 ImmuneSense™ COVID-19 Study | Coronavirus Disease (COVID-19), SARS-CoV-2 Infection | Completed | 180 | — | — | |
| NCT05054088 ImmuneSense COVID-19 Variant Study | Covid19 | Completed | 203 | — | — | |
| NCT04545333 The clonoSEQ® Watch Registry | Acute Lymphoblastic Leukemia, Adult B-Cell, Chronic Lymphocytic Leukemia | Terminated | 465 | — | — | |
| NCT04494893 ImmuneRACE - Immune Response Action to COVID-19 Events | Covid19 | Completed | 808 | — | — | |
| NCT04422314 ImmuneSense Lyme Study | Lyme Disease | Completed | 893 | — | — |